REMARKS

Reconsideration of this application, as amended, is respectfully requested.

The Applicants wish to draw the Examiner's attention to the Applicants' related copending applications and issued patents (see Appendix A) directed to nanoparticles and methods of preparation and use thereof. In particular, the Applicant draws the Examiner's attention to the Applicant's own U.S. Patent No. 6,506,564.

The Applicants note that the Examiner did not return executed copies of the PTO 1449 form for the 6th Supplemental IDS that was hand delivered to the Examiner on September 9, 4642. The Applicants request that the Examiner fully execute the PTO 1449 form for the 6th Supplemental IDS and return a copy of the executed PTO 1449 form to the undersigned representative. A copy of the 6th Supplemental IDS, associated PTO 1449 form, and PTO stamped postcard acknowledging receipt of the IDS, PTO 1449 form and references are attached. The Examiner is requested to contact the undersigned representative if the Examiner would like to have another copy of the references.

The specification was amended to update the priority claim, thus obviating the Examiner's objection to the specification. No new matter has been introduced by this amendment.

Claims 185-188 were pending in this application and were cancelled without prejudice or disclaimer. New claims 433-461 were added to further clarify the Applicants' invention. Support for the new claims can be found in the original claims and in the specification, e.g., pages 77-80. Accordingly, no new matter has been introduced into this application as a result of the present amendment.

Turning to the office action, claims 185-188 was rejected under 35 U.S.C. section 102(e) as being anticipated by Yguerabide (U.S. Patent No. 6,214,560)("Yguerabide"). The Applicants respectfully traverse this rejection.

As a general rule, for prior art to anticipate under section 102, every element of the claimed invention must be identically disclosed in a single reference. Corning Glass Works v. Sumitomo Electric, 9 U.S.P.Q.2d 1962, 1965 (Fed. Cir. 1989). The exclusion of a claimed element, no matter how insubstantial or obvious, from a reference is enough to negate anticipation. Connell v. Sears, Roebuck & Co., 220 U.S.P.Q 193, 1098 (Fed. Cir. 1983).

Applicants respectfully submit that Yguerabide cannot be applied to support an anticipation rejection of the new claims under 35 U.S.C. section 102(e).

Specifically, the Examiner alleged that Yguerabide taught detection and measurement of one or more analytes in a sample using particles of specific composition and size using light scattering. The discussion is found starting in col. 82, line 35, of Yguerabide. Col. 83 provides further discussion regarding particle size and particle binding to a surface. There is no discussion of any nanoparticle-oligonucleotide conjugate prepared by the aging process recited in the claims. See claim 433. Nanoparticle-oligonucleotide conjugates prepared by this aging process exhibit melting (dehybridization) profiles that are extremely narrow compared to the profiles obtained using the same oligonucleotides not attached to nanoparticles, and extraordinary selectivity (detection as little as a single base difference) and sensitivity (detecting as little as 10 femtomoles of nucleic acid without amplification) have been obtained using these conjugates in such assays (see particularly Examples 5, 7 and 19) of the application. Moreover, the claimed conjugates are surprisingly more stable compared to conjugates made without the aging step (see, e.g., Example 3 of the application). New claims 433-461 recite limitations that are neither taught, made obvious, or suggested by the cited reference. Thus, the Applicant respectfully submits that Yguerabide cannot be applied to support a section 102(e) rejection of the new claims.

In conclusion, the Applicants respectfully submit that the claims in this application are in allowable condition and request a Notice to this effect.

Reconsideration of this application is respectfully requested and a favorable determination is earnestly solicited. The Examiner is invited to contact the undersigned representative if the Examiner believes that this would be helpful in expediting the prosecution of this application.

Dated:

McDonnell Boehnen Hulbert & Berghoff, Ltd. 300 South Wacker Drive Chicago, IL 60606

Telephone: 312-913-0001 Facsimile: 312-913-0001 Respectfully submitted,

Emily Miao

Reg. No. 35,285



APPENDIX A

ATTY	Serial No./		
Case No.	Filing Date	Inventors/Title	Status
00-653-A	U.S. 09/927,777 Filed 8/10/01	Mirkin, Letsinger, Mucic, Storhoff, Elghanian, Taton, Garamella, Li, Park/ NANOPARTICLES HAVING OLIGONUCLEOTI DES ATTACHED THERETO AND USES THEREFORE	PENDING
00-713-В1	09/923,625 Filed 8/7/01	Mirkin, Letsinger, Mucic, Storhoff, Elghanian/ NANOPARTICLES HAVING OLIGONUCLEOTI DES ATTACHED THERETO AND USES THEREFOR	PENDING
00-713-С	09/344,667, filed 6/25/99	Mirkin, Letsinger, Mucic, Storhoff, Elghanian/ NANOPARTICLES HAVING OLIGONUCLEOTI DES ATTACHED THERETO AND USES THEREFORE	U.S. Patent No. 6,361,944, issued 3/26/02
00-713-I	U.S.S.N 09/603,830 Filed 6/26/00	Mirkin, Letsinger, Mucic, Storhoff, Elghanian, Taton; NANOPARTICLES HAVING OLIGONUCLEOTI DES ATTACHED THERETO AND USES THEREFOR	U.S. Patent No. 6,506,564, issued 1/14/03
00-713-I-1	09/961,949 9/20/01	Mirkin, Letsinger, Mucic, Storhoff, Elghanian, Taton;	U.S. Patent No. 6,582,921, issued June 24, 2003

ATTY	Serial No./		
Case No.	Filing Date	Inventors/Title	Status
		NANOPARTICLES	
		HAVING	
ŀ		OLIGONUCLEOTI	
		DES ATTACHED	
		THERETO AND	
	00/055010	USES THEREFOR	DEN ID DIG
00-713-I-2	09/957,318 9/20/01	See 00-713-I-1	PENDING
00-713-I-3	09/957,313	See 00-713-I-1	U.S. Patent No.
	9/20/01		6,645,721, issued
			11/11/03
00-713-I-4	09/966,491	See 00-713-I-1	U.S. Patent No.
	9/28/01		6,610,491
			' '
00-713-I-5	09/966,312	See 00-713-I-1	ALLOWED
	9/28/01		
00-713-I-6	09/967,409	See 00-713-I-1	PENDING
	9/28/01		
00-713-I-7	09/974,500	See 00-713-I-1	ALLOWED
	10/10/01		
00.712.1.0	00/074 007	See 00-713-I-1	PENDING
00-713-I-8	09/974,007	See 00-/13-1-1	PENDING
:	10/10/01		
00-713-I-9	09/973,638	See 00-713-I-1	PENDING
00-713-1-9	10/10/01	500 00-715-1-1	LINDING
	10,10,01		
00-713-I-	09/973,788	See 00-713-I-1	ALLOWED
10	10/10/01		
00-713-I-	09/975,062	See 00-713-I-1	ALLOWED
11	10/11/01		
00-713-I-	09/975,376	See 00-713-I-1	PENDING
12	10/11/01		
00-713-I-	09/975,384	See 00-713-I-1	PENDING
13	10/11/01		
00 510 7	00/075 400	G., 00 712 I 1	ALLOWED
00-713-I-	09/975,498	See 00-713-I-1	ALLOWED

ATTY	Serial No./	Inventors/Title	Status
Case No.	Filing Date 10/11/01	Inventors/Title	Status
17	10/11/01		
00-713-I-	09/975,059	See 00-713-I-1	PENDING
15	11/11/01		
00.510.7	00/05/ (01	0.00.710.11	DEMONIC
00-713-I-	09/976,601 10/12/01	See 00-713-I-1	PENDING
16	10/12/01		
00-713-I-	09/976,968	See 00-713-I-1	PENDING
17	10/12/01		
00-713-I-	09/976,971	See 00-713-I-1	ALLOWED
18	10/12/01		
00-713-I-	09/976,863	See 00-713-I-1	PENDING
19	10/12/01		
00-713-I-	09/976,57.7	See 00-713-I-1	ALLOWED
20	10/12/01		
00-713-I-	09/976,618	See 00-713-I-1	PENDING
21	10/12/01	500 00 713 1 1	LIVERVO
00-713-I-	09/981,344	See 00-713-I-1	PENDING
22	10/15/01		
00-713-I-	09/976,900	See 00-713-I-1	PENDING
23	10/12/01	500 00-715-1-1	LINDING
00-713-I-	09/976,617	See 00-713-I-1	PENDING
24	10/12/01		
00-713-I-	09/976,378	See 00-713-I-1	PENDING
25	10/12/01	500 00-715-1-1	
00-713-i-	10/410,324	See 00-713-I-1	PENDING
26	04/10/03	No. 1	TIC D ()
00-713-L	U.S.S.N. 09/693,005	Mirkin, Letsinger, Mucic, Storhoff,	U.S. Patent No. 6,495,324, issued
	Filed 10/20/00	Elghanian/	12/17/02
	11100 10100	NANOPARTICLES	
		HAVING	
,		OLIGONUCLEOTI	
		DES ATTACHED	

ATTY	Serial No./		
Case No.	Filing Date	Inventors/Title	Status
		THERETO AND USES THEREFORE	
00-713-M	U.S.S.N. 09/693,352 Filed 10/20/00	Mirkin, Letsinger, Mucic, Storhoff, Elghanian/ NANOPARTICLES HAVING OLIGONUCLEOTI DES ATTACHED THERETO AND USES THEREFORE	U.S. Patent No. 6,417,340, issued 7/9/02
00-714-G	U.S. 09/830,620 Filed 8/15/01	Mirkin, Nguyen/ NANOPARTICLES WITH POLYMER SHELLS	PENDING
00-715-A	U.S. 09/760,500 Filed 1/12/01	Mirkin, Letsinger, Mucic, Storhoff, Elghanian, Taton; Garamella, Li/ METHOD OF ATTACHING OLIGONUCLEOTI DES TO NANOPARTICLES AND PRODUCTS PRODUCED THEREBY	ALLOWED
00-1085-A	U.S.S.N. 09/820,279 Filed 3/28/01	Mirkin,Letsinger, etc./ METHOD AND MATERIALS FOR ASSAYING BIOLOGICAL MATERIALS	ALLOWED
00-1086-A	U.S. 09/903,461 Filed 7/11/01	Letsinger, Garimella/ METHOD OF DETECTION BY ENHANCEMENT OF SILVER STAINING	U.S. Patent No. 6,602,669, Filed 8/5/03
01-565-A	USSN 10/125,194 Filed 4/18/02	Mirkin, Nguygen, Watson, Park/ OLIGONUCLEOTI DE-MODIFIED ROMP POLYMERS	PENDING

ATTY	Serial No./		1 ago
Case No.	Filing Date	Inventors/Title	Status
		AND CO-	
		POLYMERS	
01-599-A	U.S.S.N.	Storhoff/NOVEL	PENDING
	10/291,291	THIOL-BASED	
	Filed 11/08/02	METHOD FOR	
		ATTACHING	
		OLIGONUCLEOTI	
		DES TO	
		NANOPARTICLES	77777
01-661-A	U.S.S.N.	Mirkin, Cao, Jin/	PENDING
	10/034,451	DNA-MODIFIED	
	Filed 12/28/01	CORE-SHELL	
		AG/AU	
	TICCNI	NANOCRYSTALS	DEMINIC
01-661-C	U.S.S.N.	Mirkin, Cao, Jin/	PENDING
	10/153,483	DNA-MODIFIED	
	Filed 5/22/02	CORE-SHELL	
		AG/AU NANOCRYSTALS	
01 ((1 E	U.S.S.N.		PENDING
01-661-E	0.5.5.N. 10/397,579	Mirkin, Cao, Jin/ DNA-MODIFIED	PENDING
	3/26/03	CORE-SHELL	
	3/20/03	AG/AU	
		NANOCRYSTALS	
01-1565-A	U.S.S.N.	Park, Taton,	PENDING
01-1303-A	10/266,983	Mirkin/ARRAY-	LIVERIO
	Filed 10/08/02	BASED	
	11100 10100102	ELECTRICAL	
		DETECTION OF	
		DNA USING	
		NANOPARTICLE	
		PROBES	
01-1705-A	U.S.S.N.	Nam, Park,	PENDING
	10/108,211	Mirkin/BIO-	
	Filed 3/27/02	BARCODES	
		BASED ON	
		OLIGONUCLEOTI	
		DE-MODIFIED	
		NANOPARTICLES	7-17-2
02-338-B	USSN 10/172,428	Cao, Jin, Nam,	PENDING
	Filed 6/14/02	Mirkin/MULTICHA	
		NNEL DETECTION	
		USING	
	<u> </u>	NANOPARTICLE	

ATTY	Serial No./		
Case No.	Filing Date	Inventors/Title	Status
		PROBES WITH	
		RAMAN	
		SPECTROSCOPIC	
		FINGERPRINTS	
02-338-C	10/431,341	Cao, Jin, Nam,	PENDING
	5/7/03	Mirkin/MULTICHA	
		NNEL DETECTION	
		USING	
		NANOPARTICLE	
		PROBES WITH	
		RAMAN	
		SPECTROSCOPIC	
		FINGERPRINTS	